Roivant Sciences (NASDAQ:ROIV) Given “Overweight” Rating at Cantor Fitzgerald
Cantor Fitzgerald reiterated their overweight rating on shares of Roivant Sciences (NASDAQ:ROIV – Free Report) in a report issued on Tuesday morning, Benzinga reports. Several other analysts also recently weighed in on ROIV. HC Wainwright reaffirmed a buy rating and set a $18.00 price target on shares of Roivant Sciences in a research note on […]
More Stories
Leerink Partnrs Brokers Lift Earnings Estimates for KPTI
Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Free Report) – Research analysts at Leerink Partnrs upped their Q3 2025 EPS estimates for...
Sidoti Csr Issues Pessimistic Outlook for FET Earnings
Forum Energy Technologies, Inc. (NYSE:FET – Free Report) – Sidoti Csr reduced their Q3 2025 earnings per share (EPS) estimates...
CIBC Issues Positive Forecast for Nexus Industrial REIT (TSE:NXR.UN) Stock Price
Nexus Industrial REIT (TSE:NXR.UN – Get Free Report) had its price target lifted by analysts at CIBC from C$7.50 to...
Q3 Earnings Estimate for Immunocore Issued By HC Wainwright
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR – Free Report) – Investment analysts at HC Wainwright increased their Q3 2025 EPS...
Roth Capital Estimates Gaia’s Q3 Earnings (NASDAQ:GAIA)
Gaia, Inc. (NASDAQ:GAIA – Free Report) – Equities researchers at Roth Capital cut their Q3 2025 earnings per share (EPS)...
HC Wainwright Expects Increased Earnings for Exodus Movement
Exodus Movement, Inc. (NYSEAMERICAN:EXOD – Free Report) – Stock analysts at HC Wainwright increased their Q3 2025 earnings per share...